Largest review of clinical trials to date finds no increased risk of suicide in patients using Champix

Findings from the largest review of clinical trials to date to determine whether patients prescribed the smoking cessation drug Varenicline (brand name Champix in the UK) are at an increased risk of neuropsychiatric events are published online in the British Medical Journal [BMJ] today [12 Mar]. The study was carried out by researchers at the University of Bristol.
Source: University of Bristol news - Category: Universities & Medical Training Tags: International, Research; Faculty of Medicine and Dentistry, School of Social and Community Medicine, Institutes, Elizabeth Blackwell; Press Release Source Type: news